Welcome to the WCN 2021 Interactive Program
The congress will officially run on Central European Time (CET) - Rome Time
To convert the congress times to your local time Click Here
Please note that all sessions will run at their scheduled time and be followed by a LIVE Q&A/Discussion at the end
The viewing of sessions, cannot be accessed from this conference calendar. All sessions are accessible via the Virtual Platform
- Bart Van Wijmeersch (Belgium)
- Massimo Filippi (Italy)
Join this symposium to learn about the key data that have led to the EMA approval of the subcutaneous use of natalizumab, gain practical insights into using this new route of administration in clinical practice, and keep up-to-date on the latest evidence to maximize the safe, effective use of natalizumab.
The faculty will provide three presentations on the latest advances in treatment with natalizumab followed by a live question-and-answer session. During the session, the online audience can ask questions to the expert panel.
Advancing MS Care: A New Opportunity in High Efficacy Therapy
Supported by Biogen
Welcome and introduction
- Massimo Filippi (Italy)
Natalizumab: new insights with an established high-efficacy therapy
- Paolo Gallo (Italy)
Subcutaneous natalizumab: clinical trial outcomes and experience
- Bart Van Wijmeersch (Belgium)
The future of natalizumab: experience of subcutaneous dosing in practice
- Boris-Alexander Kallmann (Germany)
Closing remarks and live Q&A
- Bart Van Wijmeersch (Belgium)
- Paolo Gallo (Italy)
- Boris-Alexander Kallmann (Germany)